NEW HAVEN, Conn., May 10, 2021 /PRNewswire/ Â Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today reported financial results for the first quarter ended March 31, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, NURTEC ODT s performance, with its differentiated efficacy and safety profile, continues to be bolstered by overwhelmingly positive patient and provider sentiment to date. We are highly encouraged by the continued success of NURTEC ODT, with net revenues of $43.8 million in the first quarter exceeding expectations.
Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
- Exceeded expectations of NURTEC™ ODT (rimegepant) with net product revenue of $43.8 million for the first quarter of 2021, totaling $107.4 million in net product revenue since launch in March 2020
- Continued brand momentum for NURTEC ODT totaling more than 600,000 prescriptions from product launch to date, with more than 33,000 unique prescribers
- Advanced Neuroinnovation™ Platform with multiple Phase 3 studies results expected within the next year, and enrolled first patient in Phase 2/3 trial of oral zavegepant, prompting $100 million Royalty Pharma milestone payment
News provided by
Share this article
Share this article
As a result of an inadvertent error, the version of the earnings release Biohaven Pharmaceutical Holding Company Ltd. ( Biohaven ) issued before market open on May 10, 2021 (the Original Earnings Release ) included certain inaccurate financial and operational data
The
by
DelveInsight analyses that the market will experience a boost due to the increase in the patient pool and launch of the emerging therapies such as
Abilify, Lumateperone/ITI-007, NRX-100/NRX-101, Zuranolone, SEP-4199, and Falkieri during the forecast period.
The
report offers insights on disease comprehension, historical and forecasted epidemiology; and Bipolar Depression market trends in the 7MM (United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). The research report also covers the current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to evaluate the underlying potential of the Bipolar Depression market.